Reprinted: Medicine Intelligence NetworkThe abstract of the 2024 American Society of Clinical Oncology (ASCO) annual meeting was officially announced today. TROP2ADCsacituzumabtirumotecan (SKB264/MK-2870) jointly developed by MSD and Kolenbotai showed its eye-catching results in a phase III trial for the treatment of advanced triple negative breast cancer (TNBC), bringing a good start to the upcoming ASCO annual meeting this year.1. What is the competitive landscape?TROP2, also known as Trophobl

Source: "Medical Research and Publication" Author: Yu Jian 1 ► Based on mRNA therapy - In the past, messenger RNA (mRNA) was a single stranded molecule responsible for transferring genetic information from deoxyribonucleic acid (DNA) to ribosomes. Ribosomes then decode genetic information and synthesize proteins. The mRNA therapy to be discussed here refers to the use of mRNA based drugs developed for the treatment or prevention of diseases. In recent years, the technology of in vitro transcription (IVT) of mRNA has gradually attracted the interest and attention of scientists in research institutions and R&D departments of biopharmaceutical companies. Biomedical companies use mRNA based technology platforms to develop targeted drug delivery methods, making drugs more precise and personalized. And with the collaboration of genetic engineering

On August 10th, the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that the third indication of ZT002 injection, a new drug of class 1 in peptide biology, has been granted implied permission for clinical trials and is intended to be developed for the treatment of Alzheimer's disease. According to public information, ZT002 is a long-acting GLP-1 receptor agonist that has the potential to be injected only once a month. Previously, the product has been approved for clinical use in China for weight loss treatment of adult obese or overweight patients, as well as the indication of blood sugar control for adult type 2 diabetes patients. Screenshot source: According to publicly available information on the CDE official website, GLP-1 drugs regulate human metabolism by activating GLP-1 receptors. They are a class of metabolic disease treatment drugs that have received widespread attention in recent years, with good effic

On May 19, 2023, Krystal Biotech's Vyjuvek (beremagene geperpavec) was approved by the FDA for the treatment of dystrophic epidermolysis bullosa (DEB) aged 6 months and older. Vyjuvek is an off the shelf topical gene therapy that uses genetically engineered HSV-1 vectors for gene delivery. Its aim is to provide two normal copies of the COL7A1 gene to patients' skin cells, generating functional type VII collagen (COL7) protein and targeting the fundamental mechanism that causes DEB. The approval of this drug has won multiple "firsts". Krystal Biotech pointed out that Vyjuvek is the first topical gene therapy approved by the FDA, the first gene therapy that can be administered repeatedly, and also the first approved treatment for DEB

On May 18th, Bausch+Lomb and Novaliq announced that the US FDA has approved perfluorohexane octane eye drops (formerly known as NOV03) for the treatment of signs and symptoms of dry eye syndrome. This is an innovative therapy for dry eye syndrome that directly targets tear evaporation. Public information shows that Hengrui Pharmaceutical has exclusive rights to the drug in China and has submitted a marketing application for the drug in China. Dry eye disease (DED) is a common ocular surface disorder typically associated with meibomian gland dysfunction (MGD). It is estimated that 86% of patients with dry eye syndrome have excessive evaporation of tears, with MGD being the main cause. The meibomian gland is the only natural source of the lipid layer in the tear film, and its dysfunction can lead to abnormal eyelid fat, ultimately resulting in excessive evaporation of tears. Currently, clinical treatment methods such as physical therapy and artificial tears exist due to various reasons

12: 2. Oppose the accelerated approval of obeticolic acid as the first NASH drug. 15: 1. Agree to postpone the approval of obeticolic acid to wait for more critical data. The 8-hour FDA Gastrointestinal Drug Expert Advisory Committee (GIDAC) and Intercept's Ocaliva (OCA) launched the FDA's first NASH (non-alcoholic steatohepatitis) drug, which can be described as a complete failure. NASH is a severe type of non-alcoholic fatty liver disease (NAFLD), defined as liver steatosis of more than 5%, accompanied by inflammation, liver cell damage, and with or without fibrosis. Due to the irreversible damage caused by chronic inflammation and liver fibrosis during the NASH stage, it is considered a critical stage for the progression of end-stage liver diseases such as cirrhosis, liver failure, or hepatocellular carcinoma. An Epidemiological Study in 2018